NCT05729646 is a Phase 2 clinical trial of Toripalimab in Adenocarcinoma of the Stomach, sponsored by Yu jiren.

Who is sponsoring NCT05729646?

NCT05729646 is sponsored by Yu jiren.

What drugs are being tested in NCT05729646?

Interventions in NCT05729646: Toripalimab, Oxaliplatin, S1.

What condition does NCT05729646 study?

NCT05729646 studies Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency.

Is NCT05729646 still recruiting?

NCT05729646 is currently recruiting now. Last updated 25 July 2023.

Last reviewed 2023-07-25 · How we verify

NCT05729646

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting now Phase 2 Last updated 25 July 2023

What this trial tests

Phase 2 trial testing Toripalimab in Adenocarcinoma of the Stomach in 90 participants. Currently enrolling.

Timeline

31 May 2023

Primary endpoint
28 February 2026

28 February 2029

Quick facts

Lead sponsor	Yu jiren
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	31 May 2023
Primary completion	28 February 2026
Estimated completion	28 February 2029
Sites	8 locations across China

Drugs / interventions tested

Toripalimab (TORIPALIMAB) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
S1 — full drug profile →

Conditions studied

Adenocarcinoma of the Stomach — all drugs for Adenocarcinoma of the Stomach →
Adenocarcinoma of Esophagogastric Junction — all drugs for Adenocarcinoma of Esophagogastric Junction →
Mismatch Repair Deficiency — all drugs for Mismatch Repair Deficiency →

Sponsor

Yu jiren — full company profile →

Who can join

Adults 18 to 80, any sex, with Adenocarcinoma of the Stomach or Adenocarcinoma of Esophagogastric Junction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multi-center, randomized controlled phase II trial to compare the efficacy of perioperative SOX plus toripalimab, toripalimab monotherapy with SOX regimen in participants with dMMR locally advanced gastric or esophagogastric junction adenocarcinoma

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical status and future prospects of neoadjuvant immunotherapy for localized mismatch repair-deficient cancers: a review.
Li J. · · 2024 · cited 3× · PMID 38768473 · DOI 10.1097/js9.0000000000001680

Verify or expand the search:

Other trials of Toripalimab

Trials testing the same drug.

NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07423078 — Window of Opportunity in Preserving Laryngeal Function Trial · Phase 2 · recruiting
NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting

Other recruiting trials for Adenocarcinoma of the Stomach

Currently open trials in the same condition.

NCT05872685 — Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS- · Phase 2 · recruiting
NCT05715931 — Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastri · Phase 2 · recruiting
NCT06121700 — Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer · Phase 2 · recruiting
NCT04878783 — Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG · active not recruiting

Other Yu jiren trials

Trials by the same sponsor.

NCT05872685 — Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS- · Phase 2 · recruiting
NCT05970627 — Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastri · Phase 2 · not yet recruiting
NCT05715931 — Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastri · Phase 2 · recruiting
NCT04515615 — Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05729646 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yu jiren
Last refreshed: 25 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05729646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing